- Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
2012/11/03 by Hans‐Henrik Parving, Barry M. Brenner, John J.V. McMurray +11 · 1,325 citations
Medicine · #Renin-Angiotensin System Studies #Hormonal Regulation and Hypertension #Heart Failure Treatment and Management #Aliskiren #Type 2 diabetes #Medicine #Internal medicine #Diabetes mellitus #Cardiology #Endocrinology #Renin–angiotensin system
- Aliskiren and Dual Therapy in Type 2 Diabetes Mellitus
2008/06/04 by Julie R. Ingelfinger · 41 citations
Medicine · #Renin-Angiotensin System Studies #Hormonal Regulation and Hypertension #Blood Pressure and Hypertension Studies #Renin–angiotensin system #Aliskiren #Medicine #Angiotensin II #Vasoactive #Internal medicine #Angiotensin II receptor type 1 #Aldosterone #Endocrinology #Pharmacology #Receptor #Blood pressure
- Oral renin inhibitors
2006/09/28 by Jan A. Staessen, Jan A Staessen, Yan Li +2 · 215 citations
Medicine · #Aliskiren #Bioavailability #Blood pressure #Coagulation, Bradykinin, Polyphosphates, and Angioedema #Hormonal Regulation and Hypertension #Internal medicine #Medicine #Oral administration #Orally active #Pharmacodynamics #Pharmacokinetics #Pharmacology #Plasma renin activity #Renin inhibitor #Renin-Angiotensin System Studies #Renin–angiotensin system
- Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients
2005/02/22 by Alan H. Gradman, Roland E. Schmieder, R. Lins +3 · 524 citations
Medicine · #Renin-Angiotensin System Studies #Heart Failure Treatment and Management #Blood Pressure and Hypertension Studies #Aliskiren #Medicine #Placebo #Irbesartan #Tolerability #Blood pressure #Urology #Internal medicine #Pharmacology #Renin–angiotensin system #Endocrinology #Adverse effect